| Home > Site Map > Recommendations > E > Estrogen Replacement |
| Therefore, the results of studies using Premarin® can not necessarily be applied to bioidentical estrogens. These compounds may be compounded by a pharmacist, or bought under names such as Estrace®, Estring®, Alora®, Estraderm®, Climara®, Vivelle®, FemPatch™, Menostar™, EstroGel®, Estrasorb™, Premarin®, Premphase™, Prempro™, or as their generic form. They come in the form of oral capsules, vaginal tablets, vaginal suppositories, vaginal creams, facial serum, transdermal cream or gel, sublingual tablet, oral tablet, vaginal rings, transdermal patches, or transdermal emulsion. The different forms are probably of equal efficacy. The patches don't seem to provide the same degree of beneficial effect on the cholesterol as does oral estrogen. Reasons For Use Menopause usually occurs around the age of fifty years old and occurs secondary to failure of the ovaries to produce estrogen and progestin, which are the female hormones. Symptoms vary from only the cessation periods to a multitude of annoying symptoms such as sweating, hot flashes, fatigue, vaginal drying, pain with intercourse, low sex drive and depression. This markedly increases the risk of bone fractures. Collapse of the vertebrae in elderly women can occur because of the thin, weak bones. Unfortunately the process of osteoporosis is not reversible with estrogen replacement therapy. The total cholesterol will increase and the good (HDL) cholesterol will decrease. Estrogen replacement therapy prevents these changes and will reduce the risk of dying from a heart attack by about 35%. Testosterone, which benefits libido and bone health, may also be prescribed. One study showed that taking estrogen after menopause was associated with an increased life expectancy of up to 2.3 years. The addition of progestin to the estrogen will slightly decrease the beneficial effect that estrogen has on lowering cholesterol. However, in most women the symptoms are mild and will resolve after a few months of therapy. For the first three to six months, vaginal spotting will occur in 30% to 50% of women taking continuous estrogen and progestin. This bleeding will generally stop permanently in about 95% of women within a six-month period. |
| Estrogens Low High Female Testosterone Level Susceptibility To Miscarriages Vulvodynia / Vestibulitis |